JP2010523559A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523559A5
JP2010523559A5 JP2010502079A JP2010502079A JP2010523559A5 JP 2010523559 A5 JP2010523559 A5 JP 2010523559A5 JP 2010502079 A JP2010502079 A JP 2010502079A JP 2010502079 A JP2010502079 A JP 2010502079A JP 2010523559 A5 JP2010523559 A5 JP 2010523559A5
Authority
JP
Japan
Prior art keywords
phenoxy
polymorph
diethylamine
chloro
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010502079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003325 external-priority patent/WO2008123914A1/en
Publication of JP2010523559A publication Critical patent/JP2010523559A/ja
Publication of JP2010523559A5 publication Critical patent/JP2010523559A5/ja
Pending legal-status Critical Current

Links

JP2010502079A 2007-04-05 2008-03-12 [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態 Pending JP2010523559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23
PCT/US2008/003325 WO2008123914A1 (en) 2007-04-05 2008-03-12 Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Publications (2)

Publication Number Publication Date
JP2010523559A JP2010523559A (ja) 2010-07-15
JP2010523559A5 true JP2010523559A5 (enExample) 2011-03-31

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010502079A Pending JP2010523559A (ja) 2007-04-05 2008-03-12 [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態

Country Status (11)

Country Link
US (2) US7884219B2 (enExample)
EP (1) EP2144883A1 (enExample)
JP (1) JP2010523559A (enExample)
AR (1) AR065896A1 (enExample)
CA (1) CA2681864A1 (enExample)
CL (1) CL2008000987A1 (enExample)
PA (1) PA8775601A1 (enExample)
PE (1) PE20090808A1 (enExample)
TW (1) TW200900384A (enExample)
UY (1) UY31004A1 (enExample)
WO (1) WO2008123914A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ,インコーポレイテッド [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態
EP2470510B1 (en) 2009-09-30 2014-05-14 TransTech Pharma, LLC Substituted imidazole derivatives for treatment of alzheimers disease.
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
SG11201502210VA (en) * 2012-10-05 2015-04-29 Vtvx Holdings I Llc Treatment of mild and moderate alzheimer's disease
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101597262A (zh) * 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
MXPA05012350A (es) * 2003-05-20 2006-05-25 Transtech Pharma Inc Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma.
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ,インコーポレイテッド [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態

Similar Documents

Publication Publication Date Title
JP2010523559A5 (enExample)
JP2014501282A5 (enExample)
Sun et al. A green luminescent 1-D helical tubular dipyrazol-bridged cadmium (II) complex: a coordination tube included in a supramolecular tube
JP2019505499A (ja) ボリコナゾール中間体及びボリコナゾールの合成方法
JP2016513060A5 (enExample)
CN104447804B (zh) 间苯双三唑Cu-三氟甲磺酸配合物及其制备方法与应用
CN103242193B (zh) 一种羟肟化杯[6]芳烃高效铀萃取剂的制备及其用途
WO2007047838A2 (en) Process for preparing olmesartan medoxomil
WO2010010454A2 (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
CN104662019A (zh) 制备阿齐沙坦奥美沙坦酯的高纯度钾盐的方法
EP2809665A1 (en) Process for the preparation of vilazodone or its pharmaceutically acceptable salts
JP6041985B2 (ja) 結晶型t−ブチル2−[(4R,6S)−6−ホルミル−2,2−ジメチル−1,3−ジオキサン−4−イル]アセテート及びその製造方法
CN103755644B (zh) 化合物、其合成及用其合成双UPy取代化合物的方法
CN104370900B (zh) 一种盐酸阿罗洛尔的制备方法
CN105777617B (zh) 色瑞替尼的合成中间体及其制备方法
JP2012524736A5 (enExample)
WO2017131218A1 (ja) アジルサルタン及びその製造方法
CN102531970A (zh) 碳酰肼及其快速合成方法
CN103664901B (zh) 一种苯甲酸利扎曲坦制备方法
CN119255852A (zh) 吡啶酰胺杀真菌剂化合物的结晶形式
JP7177796B2 (ja) アジルサルタンa型結晶の製造方法
CN102050796B (zh) α,α,α',α'-四甲基-5-(1氢-1,3,4-三氮唑-1-基甲基)-1,3-苯二乙腈的制备方法
JP4921497B2 (ja) 多環式3級アミンの製造方法
JP5575783B2 (ja) トリフェニルメタン保護基の除去方法
CN103319472B (zh) 一种伊潘立酮的制备方法